300+
Patients samples processed
94.4%
Sensitivity (vs OncoDiscover®)
9+
Cancer types tested
The OncoMetastat® device
OncoMetastat® Device
For research use only. Safety and effectiveness have not been established.
OncoMetastat® Digital Screen and pump
OncoMetastat® Components
Our
Publications
In collaboration with researchers and thought leaders around the world, OncoMetastat® combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind the technology is supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc
1 Sept 2026
Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients
A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease.
30 Aug 2026
Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients
This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions.
Be informed.
Be a fighter.
14 Mar 2026
Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control
Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer.